Protein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells

Lobaplatin is a third-generation platinum-based antineoplastic agent and is widely used for osteosarcoma treatment before and after tumor removal. However, treatment failure often results from lobaplatin drug resistance. In our study, we found that SaOS-2 and SOSP-9607 osteosarcoma cells became less...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huan, Li, Bin, Yan, Kang, Wu, Yonghong, Wen, Yanhua, Liu, Yunyan, Fan, Pei, Ma, Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006349/
https://www.ncbi.nlm.nih.gov/pubmed/33791202
http://dx.doi.org/10.3389/fonc.2021.602712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006349/
https://www.ncbi.nlm.nih.gov/pubmed/33791202
http://dx.doi.org/10.3389/fonc.2021.602712

Ejemplares similares